The aerospace and defence contractor revealed its order intake totalled £488million in the six months ending April, a 42 per cent annual increase.Read More

You might also be interested in reading Arvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson’s Disease and Movement Disorders®.